Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort
Open Access
- 3 July 2025
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 226, 115595
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN studyESMO Open, 2024
- Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyLung Cancer, 2024
- ESMO Guidance for Reporting Oncology real-World evidence (GROW)Annals of Oncology, 2023
- Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung CancerClinical Lung Cancer, 2023
- Trends in the epidemiology of small-cell lung cancer: a Dutch nationwide population-based study over 1989–2020European Journal of Cancer, 2023
- Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysisLung Cancer, 2023
- Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesotheliomaEuropean Journal of Cancer, 2022
- Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANESMO Open, 2022
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Annals of Oncology, 2021
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialThe Lancet Oncology, 2020